In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
24 authors at 5 institutions in 4 countries.
Linda ZhangTranslational Biology and Molecular Medicine Graduate Program, Baylor College of Medicine, Houston, TX.ORCID 0000-0002-5777-2357 Joanne I HsuTranslational Biology and Molecular Medicine Graduate Program, Baylor College of Medicine, Houston, TX.ORCID 0000-0002-1194-0650 Etienne D BraekeleerDepartment of Haematology, Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge.ORCID 0000-0003-4659-023X Tajhal D PatelTexas Children's Hospital Department of Hematology/Oncology, Baylor College of Medicine, Houston, TX.
Alejandra G MartellDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX.
Anna G GuzmanDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX.
Katharina WohlanDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX.ORCID 0000-0002-9147-4070 Hidetaka UryaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Ayala TovyStem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston TX.
Elsa CallenLaboratory of Genome Integrity, National Cancer Institute, National Institute of Health, Bethesda, MD.
Rebecca MurdaughStem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston TX.
Rosemary RichardStem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston TX.
Sandra JansenDonders Centre for Neuroscience, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0001-9453-8124 Lisenka VissersDonders Centre for Neuroscience, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0001-6470-5497 Bert B A de VriesDonders Centre for Neuroscience, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0002-2789-2120 Andre NussenzweigCancer and Cell Biology Graduate Program, Baylor College of Medicine, Houston, TX.
Cristian CoarfaDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX.ORCID 0000-0002-4183-4939 Koichi TakahashiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-8027-9659 George VassiliouDepartment of Haematology, Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge.ORCID 0000-0003-4337-8022 Margaret A GoodellStem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston TX.ORCID 0000-0003-1111-2932 Baylor College of Medicine · USRadboud University Nijmegen · NLThe University of Texas MD Anderson Cancer Center · USWellcome/MRC Cambridge Stem Cell Institute · GBNational Cancer Institute · US
Funding
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9MProject 3: Contribution of inflammation and DNA damaging factors to clonal expansion and malignant transformation in a community cohort of older adultsP01CA265748 · NCI · BAYLOR COLLEGE OF MEDICINE · PI ELIZABETH A. PLATZ · 2022 to 2026
$13.6MPPM1D in Clonal Hematopoiesis and MalignanciesR01CA237291 · NCI · BAYLOR COLLEGE OF MEDICINE · PI MARGARET A. GOODELL, Koichi Takahashi · 2019 to 2026
$3.7MMECHANISMS OF POL II ELONGATION IN DIFFUSE MIDLINE GLIOMAR01NS129860 · NINDS · BAYLOR COLLEGE OF MEDICINE · PI Jamie N. Anastas · 2023 to 2026
$1.8MBD Biosciences Special Order LSRIIS10RR024574 · NCRR · BAYLOR COLLEGE OF MEDICINE · PI LUMPKIN, ELLEN A · 2009 to 2009
$430kQuanterix 2470 Arrayer for Reverse Phase Protein Array TechnologyS10OD028648 · OD · BAYLOR COLLEGE OF MEDICINE · PI HUANG, SHIXIA · 2020 to 2020
$300kCancer Research UK 23015NCI NIH HHS P01 CA265748NCI NIH HHS P30 CA125123NCI NIH HHS R01 CA237291NCRR NIH HHS S10 RR024574NIH HHS S10 OD028648NINDS NIH HHS R01 NS129860
6 · The paper itselfAbstract
The DNA damage response is critical for maintaining genome integrity and is commonly disrupted in the development of cancer. PPM1D (protein phosphatase, Mg2+/Mn2+ dependent 1D) is a master negative regulator of the response; gain-of-function mutations and amplifications of
Identifiers
PMID37693622
PMCPMC10491179
OpenAlexW4386351587
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390